Pharmacy benefit management unicorn Capital Rx hits $3.5 billion in revenue with a different approach to drug pricing as Congress targets middlemen
Healthcare startup Capital Rx seeing revenue surge as Congress seeks to regulate the PBM giants that profit from high drug ...
BioSpace3d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
Psychedelic: Relmada acquires neurosteroid from Asarina
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on an acquisition, study results ...
Le Lézard4d
Demron Selected as Key Material for Mars Spacesuit Development
Radiation Shield Technologies (RST) proudly announces that its groundbreaking anti-radiation fabric, Demron, has been chosen as a critical component in the design of the Mars Spacesuit. Highlighted in ...
Le Lézard4d
Response Pharmaceuticals Announces Early Completion of Enrollment of a Phase 2 Study Evaluating RDX-002 Treating Patients Discontinuing GLP-1 Agonists
Response Pharmaceuticals, Inc., a clinical-stage company focused on weight management and metabolic health in high-risk populations, today announced the early completion of enrollment in a Phase 2 ...
NurExone Biologic Inc: NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) ("NurExone" or the "Company") is pleased to announce the formation of a U.S.-based ...
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions
ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.
NurExone Forms Exo-Top Inc. in the U.S. for Exosome Manufacture and Commercialization
Exo-Top was established under the jurisdiction of the State of Nevada. Basing Exo-Top in the U.S. offers key advantages, including proximity to strategic partners, access to a robust biopharma ...
BWX Technologies: A Competitive Advantage In New Nuclear
BWX Technologies has a substantial competitive advantage in the new nuclear market. Click here to find out why I rate BWXT a ...
BioSpace6d
Algiax’s Non-Opioid Drug Reduces Neuropathic Pain in Mid-Stage Trial
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...